兰菌净防治儿童反复呼吸道感染疗效观察

The therapeutic effect of Lantigen B on infantile recurrent respiratory tract infection

为探讨兰菌净治疗小儿反复呼吸道感染(RRI)的疗效及其副作用,采用随机开放对照法.给予常规抗感染对症治疗,治疗组在常规治疗基础上加用兰菌净.结果显示,兰菌净组血清中IgA/(g/L)从3.25±3.52升高到6.25±6.71,CD系列值提高,CD3/%从62.47±7.72升高到66.6±6.62,CD4/%从33.8±8.03升高到37.6±7.31,P<0.01.兰菌净组较对照组呼吸道感染次数减少,治疗后5个月累计感染次数为(2.20±1.42)次,而对照组为(3.60±1.93)次,两者相比P<0.01;感染的持续时间缩短,兰菌净组平均为(2.03±1.74)d,对照组为(3.65±2.06)d,P<0.01.疗程结束后3个月兰菌净组使用抗生素天数明显减少.兰菌净组有效率73.8%,对照组有效率40.3%.兰菌净组服药过程中,有3例出现皮肤皮疹,1例出现食欲下降,未见其他副作用.兰菌净治疗RRI患儿,可以使CD3、CD4及血清IgA水平明显升高,减少感染次数,临床上安全有效.

To explore the therapeutic effect and side-effect of Lantigen B to children with recurrent respiratory tract infection(RRI).Randomized open control method was utilized in this study.The Lantigen B group was treated with Lantigen B.The serum level of IgA/(g/L) increased from 3.25±3.52 to 6.25±6.71 in the Lantigen B group,and the values of CD series also increased.The values of CD3/% enlarged from 62.47±7.72 to 66.6±6.62,while that of CD4/% from 33.8±8.03 to 37.6±7.31,P<0.01.The infection times in the Lantigen B group was significeantly less than in control group(P<0.01).The cumulative infection times in the Lantigen B group was 2.20±1.42 for five months after treatment,and that in the Control B group was 3.60±1.93.The duration of infection in the Lantigen B group was significantly shorter than that in the control group(P<0.01).The mean of infection duration in the Lantigen B group was(2.03±1.74) d,and that in the control group was(3.65±2.06) d.The time for the utilization of antibiotics in the Lantigen B group was less than that in control group in three month after treatment(P<0.01).The effective percentage in the Lantigen B group was 73.8%,and that in the control group was 40.3%.Three cases of erythra were observed during medication in the Lantigen B group,and one case of inappetence occurred,other side-effects were not observed.With the application of Lantigen B in the therapy of recurrent respiratory tract infection,the levels of CD3,CD4 and IgA increased markedly,indicating that Lantigen B was safe and effective to children with RRI clinically.